PPD01.02 Repotrectinib in Patients With ROS1 Fusion-Positive (ROS1+) NSCLC: Update From the Pivotal Phase 1/2 TRIDENT-1 TrialAlexander Drilon, Byoung Chul Cho, Benjamin Besse et al.|Journal of Thoracic Oncology|2024Cited by 0